A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin

Drug-drug Interaction Clinical Trial

Official title:

A Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study to Evaluate the Effects of Tucatinib of the Pharmacokinetics of Metformin in Healthy Male and Female Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03826602
• Other study ID #: SGNTUC-020
• Status: Completed
• Phase: Phase 1
• Start date: February 12, 2019
• Est. completion date: March 15, 2019

Study information

• Verified date: March 2019
• Source: Seattle Genetics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being done to look at how tucatinib might affect the way another drug (metformin) works. It will look at healthy volunteers and how tucatinib affects how the body absorbs metformin. This will help us find out whether tucatinib is safe to give together with metformin. The study will also look at how tucatinib affects how the kidneys work.

Description:

This is a single center, fixed-sequence, drug-drug interaction study to assess the effects of multiple oral doses of tucatinib on the pharmacokinetics of a single oral dose of metformin in healthy subjects. The primary objective of the study is to assess the effects of tucatinib on the single-dose PK of metformin. Secondary objectives of the study are to (1) assess the safety and tolerability of metformin when coadministered with tucatinib and (2) assess the effects of tucatinib on renal function using iohexol as glomerular filtration rate (GFR) marker.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: March 15, 2019
• Est. primary completion date: March 8, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Healthy status, as defined by the absence of evidence of any clinically significant findings

• Males must agree to use a barrier method of birth control and not donate sperm during study plus 30 days after last dose of study drug

• Weight of =60kg

• Body mass index between 18.0 and 32.0 kg/m² (inclusive)

• Ability to abstain from alcohol-, caffeine-, and xanthine-containing food and beverages from 48 hours prior to admission through study discharge

• All nonregular medication (including over-the-counter medication, health supplements, and herbal remedies) must be stopped at least 28 days prior to admission

Exclusion Criteria:

• Females who are of childbearing potential or lactating

• Males with female partners who are pregnant, lactating, or planning to become pregnant within 30 days of the study

• Use of any investigational drug or device within 30 days of study start

• Use of tobacco products within 21 days prior to admission

• Routine or chronic use of more than 3 grams of acetaminophen daily

• Strenuous activity, sunbathing, and contact sports within 72 hours prior to first admission and for the duration of the study

• Blood transfusion within 90 days of study drug administration

• History of alcoholism or drug abuse within 2 years

• History of alcohol consumption exceeding 7 drinks/week for female participants or 14 drinks/week for male subjects

• History of donation of more than 450 mL of blood within 60 days prior to dosing, or planned donation before 30 days have elapsed since intake of study drug

• Plasma or platelet donation within 7 days of initial study drug administration

• Positive screening test for Hepatitis B, Hepatitis C, or HIV 1 or 2 (human immunodeficiency virus)

• Acute or chronic metabolic acidosis, including diabetic ketoacidosis

• Renal disease or dysfunction as suggested by serum creatinine levels or abnormal creatinine clearance

Related Conditions & MeSH terms

• Drug-drug Interaction

Intervention

Drug:
• Tucatinib
150mg administered orally twice daily
• Metformin
850mg administered orally
• Iohexol
1500 mg administered intravenously (IV)

Locations

Country	Name	City	State
United States	Pharmaceutical Research Associates	Salt Lake City	Utah

Sponsors (1)

Lead Sponsor	Collaborator
Seattle Genetics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum observed plasma concentration (Cmax) of metformin		Up to 9 days
Primary	Time to maximum observed plasma concentration (tmax) of metformin		Up to 9 days
Primary	Half-life (t1/2) of metformin		Up to 9 days
Primary	Area under the plasma concentration-time curve from time 0 to the last available measurement (AUC0-last) of metformin		Up to 9 days
Primary	Area under the plasma concentration time curve to time 0 extrapolated to infinity (AUC0-inf) of metformin		Up to 9 days
Primary	Apparent volume of distribution (V2/F) of metformin		Up to 9 days
Primary	Oral clearance (CL/F) of metformin		Up to 9 days
Secondary	Incidence of adverse events (as assessed by AE assessments, clinical laboratory tests, physical examinations, vital signs measurements, and 12-lead electrocardiogram)		Up to 16 days
Secondary	Glomerular Filtration Rate (GFR) as measured by iohexol plasma clearance		Up to 8 days